• Cannabidiol Attenuates Orofacial Pain via Endocannabinoid Pa

  2026-08-05

  This study introduces a multidimensional analysis of cannabidiol (CBD) in orofacial inflammatory pain, revealing both peripheral and central mechanisms that underlie its analgesic and affective benefits. The research highlights the pivotal role of endocannabinoid system modulation, particularly through CB1 and CB2 receptors, and provides a rigorous behavioral and molecular framework for future cannabinoid receptor research.

• Aloin Isoforms Selectively Inhibit SARS-CoV-2 PLpro In Vitro

  2026-08-05

  The reference study demonstrates that aloin A and B, components of some oral rinse products, uniquely and selectively inhibit both the proteolytic and deubiquitinating activity of SARS-CoV-2 PLpro in vitro. This mechanistic insight refines our understanding of antiviral potential among oral antimicrobial agents and informs future research protocols.

• CKI 7 dihydrochloride: Casein Kinase 1 Inhibitor for Metasta

  2026-08-04

  CKI 7 dihydrochloride empowers researchers to dissect Casein kinase 1 signaling in advanced cancer models, with robust applications in Wnt pathway modulation and circadian biology. This article translates bench findings into actionable protocols, troubleshooting advice, and comparative insights for pathway-targeted oncology research.

• MK-1775 (Wee1 Kinase Inhibitor): Mechanism, Evidence & Limit

  2026-08-04

  MK-1775 is a potent Wee1 kinase inhibitor that abrogates the G2 DNA damage checkpoint, sensitizing p53-deficient tumor cells to DNA-damaging agents. Its high selectivity and defined mechanism make it a core reagent for translational oncology research.

• V5 Epitope Tag Peptide: Precision Tagging for Protein Detect

  2026-08-03

  The V5 Epitope Tag Peptide empowers researchers with high-purity, robust detection and flexible multiplexing in recombinant protein workflows. Its optimized sequence and solubility, combined with innovations in antibody screening, set a new benchmark for reproducibility and sensitivity across Western blotting, immunoprecipitation, and advanced microscopy.

• Discovery and Characterization of MK 0893: A Potent Glucagon

  2026-08-03

  The reference study reports the discovery and preclinical evaluation of MK 0893, a highly selective and orally bioavailable glucagon receptor antagonist for type 2 diabetes research. This work demonstrates MK 0893's nanomolar potency, selectivity, and efficacy in both in vitro and in vivo models, shaping subsequent molecular design and experimental protocols.

• GLT-1 Upregulation Reduces Neuronal Death via CB1-CREB Pathw

  2026-08-02

  This study reveals that enhancing GLT-1 expression in astrocytes mitigates neuronal apoptosis and cognitive dysfunction in traumatic brain injury (TBI) by inhibiting the CB1-CREB signaling pathway. These mechanistic insights advance targeted neuroprotection strategies and inform future research on cannabinoid receptor modulation in brain injury.

• Y-27632 ROCK Inhibitor: Parameters, Workflows, and QC Guide

  2026-08-01

  Y-27632 is a highly selective ROCK1/2 inhibitor that enables precise modulation of cytoskeletal dynamics, making it indispensable for cell biology and cancer research. It is best suited for controlled in vitro studies of actin stress fiber formation and ROCK signaling, but is not recommended for diagnostic or medical applications. Researchers should follow strict handling and solubility practices to ensure reproducibility.

• Ferrostatin-1 (Fer-1): Data-Driven Solutions for Reliable Fe

  2026-07-31

  This article delivers scenario-based, evidence-backed guidance for leveraging Ferrostatin-1 (Fer-1), SKU A4371, in cell viability and cytotoxicity assays where ferroptosis modulation is critical. Practical recommendations are grounded in quantitative literature and real-world workflow needs, emphasizing robust assay design and reliable sourcing for reproducible results.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-07-31

  Schwartz (2022) introduces a framework distinguishing relative viability and fractional viability in in vitro cancer drug assays, revealing that most compounds impact both proliferation and cell death, but in different proportions and with variable timing. This approach enhances the mechanistic interpretation of anti-proliferative and apoptosis-inducing agents, supporting the rational development and evaluation of targeted therapies.

• Pomalidomide (CC-4047): Benchmarks, Mechanisms, and Research

  2026-07-30

  Pomalidomide (CC-4047) is a next-generation immunomodulatory agent with potent activity in hematological malignancy research. It modulates the tumor microenvironment, inhibits TNF-α, and alters erythroid differentiation pathways. Quantitative evidence supports its use in multiple myeloma models and advanced workflow integration.

• ICG001 (SKU A8217): Precision Wnt/β-Catenin Inhibition in Re

  2026-07-30

  This article explores how ICG001 (SKU A8217) empowers life science researchers to achieve reproducible, quantitative insights in Wnt/β-catenin pathway studies. Through scenario-driven Q&A, we highlight evidence-based advantages in experimental design, data interpretation, and workflow reliability when using ICG001 from APExBIO.

• Baricitinib (LY3009104): Precision Protocols for JAK1/2 Inhi

  2026-07-29

  Baricitinib (LY3009104) empowers researchers to dissect JAK-STAT cytokine signaling with nanomolar precision, enabling robust modeling of inflammatory pathways and immune modulation. This guide translates recent spatial proteomics insights into actionable protocols and troubleshooting recommendations for advanced inflammation research.

• Tetraethylammonium chloride (TEAC, B7262): Precision in K+ C

  2026-07-29

  This in-depth guide addresses common laboratory challenges in K+ channel and cell viability assays and demonstrates how Tetraethylammonium chloride (SKU B7262) delivers reproducible, data-driven solutions. Evidence-backed protocol advice and scenario-based Q&A support biomedical researchers in optimizing assay performance with TEAC.

• Chloramphenicol in Plasmid Selection: Precision, Resistance,

  2026-07-28

  Explore how Chloramphenicol enables precise plasmid selection and protein synthesis inhibition in molecular biology research. This article uniquely integrates recent resistance dynamics with actionable assay insights, advancing beyond existing literature.

453 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page